Enzymotec announced today that CardiaBeat™ received Novel Food approval by the European Commission. This approval enables immediate sales and distribution in the EU for both functional foods and dietary supplements markets.
CardiaBeat™ is a sterol-based matrix, which can reduce additional cardiovascular risk factors beyond cholesterol. So far it has been sold as a dietary supplement in the US, Israel and SE-Asia.
"Plant sterol-esters have long been one of the strongest market leaders in the European Functional scene. Unfortunately, they have almost reached to the point of being commodities with only limited capacity to create additional value to the consumer. We believe that CardiaBeat™ enables the whole sterol-market to advance to the next level, by its unique combinations with monounsaturated and Omega-3 fatty acids, and by its capacity to reduce triglycerides and enable optimal fat soluble vitamins absorption" says Ms. Michal Haim-Bravman, Marketing Manager.
Earlier this year the compnay announced that CardiaBeat™ won the NutrAward prize at the SupplyExpo 2007. Criteria for choosing CardiaBeat™ included its efficacy, safety, innovativeness, scientific merit and market potential.
Enzymotec develops and produces novel ,lipid based, ingredients among which are : SharpPS™ , SharpPS™ SILVER and SharpPS™ GOLD for Improving cognitive performance and InFat™ for balanced nutrition for babies and toddlers.